Skip to main content

Aquestive Therapeutics, Inc. (AQST)

NASDAQ: AQST · Delayed Price · USD
4.43 0.21 (4.98%)
Sep 22, 2021 4:00 PM EDT - Market closed
Market Cap172.27M
Revenue (ttm)41.88M
Net Income (ttm)-63.96M
Shares Out38.89M
EPS (ttm)-1.83
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume298,887
Open4.18
Previous Close4.22
Day's Range4.17 - 4.43
52-Week Range3.10 - 8.60
Beta3.61
AnalystsBuy
Price Target15.20 (+243.1%)
Est. Earnings DateNov 2, 2021

About AQST

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with...

IndustryPharmaceuticals
IPO DateJul 25, 2018
Employees187
Stock ExchangeNASDAQ
Ticker SymbolAQST
Full Company Profile

Financial Performance

In 2020, AQST's revenue was $45.85 million, a decrease of -12.85% compared to the previous year's $52.61 million. Losses were -$55.78 million, -15.79% less than in 2019.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for AQST stock is "Buy." The 12-month stock price forecast is 15.20, which is an increase of 243.12% from the latest price.

Price Target
$15.20
(243.12% upside)
Analyst Consensus: Buy

News

Aquestive Therapeutics to Participate in 12th Annual Wedbush PacGrow Healthcare Virtual Conference

WARREN, N.J., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...

1 month ago - GlobeNewsWire

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 21.43% and 44.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Aquestive Therapeutics Reports Second Quarter 2021 Financial Results, Provides Business Update and Raises Full Year R...

WARREN, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patien...

1 month ago - GlobeNewsWire

Earnings Preview: Aquestive Therapeutics (AQST) Q2 Earnings Expected to Decline

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

4 Stocks To Watch With The Stock Market Down Today

Which Penny Stocks Are Investors Watching After the Stock Market Crash? The post 4 Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | P...

Other symbols:JAGX
2 months ago - PennyStocks

Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant™ (diazepam) ...

WARREN, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...

2 months ago - GlobeNewsWire

Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film

WARREN, N.J., June 24, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...

2 months ago - GlobeNewsWire

Aquestive Therapeutics Announces Leadership Transition of Chief Financial Officer

WARREN, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...

3 months ago - GlobeNewsWire

Aquestive Therapeutics to Participate in JMP Securities and BMO Capital Market Investor Conferences

WARREN, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...

3 months ago - GlobeNewsWire

Aquestive Therapeutics to Participate in 2021 RBC Capital Markets Global Healthcare Conference

WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patien...

4 months ago - GlobeNewsWire

Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 6.82% and 21.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Aquestive Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

WARREN, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patient...

4 months ago - GlobeNewsWire

DEADLINE TODAY: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. an...

Los Angeles, California--(Newsfile Corp. - April 30, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutic...

4 months ago - Newsfile Corp

AQST Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Aquestive Therapeutics, Inc. Investors of Class Actio...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or "th...

4 months ago - Business Wire

AQST Final Deadline Today: Rosen, Trusted National Trial Counsel, Encourages Aquestive Therapeutics, Inc. Investors w...

New York, New York--(Newsfile Corp. - April 30, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) betwee...

4 months ago - Newsfile Corp

AQST IMPORTANT DEADLINE FRIDAY: ROSEN, A LEADING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors with Los...

NEW YORK, April 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2...

4 months ago - PRNewsWire

DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc....

Los Angeles, California--(Newsfile Corp. - April 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutic...

4 months ago - Newsfile Corp

APRIL 30, 2021 AQST INVESTOR DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaint...

New York, New York--(Newsfile Corp. - April 29, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securi...

4 months ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST

New York, New York--(Newsfile Corp. - April 28, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such i...

4 months ago - Newsfile Corp

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive ...

LOS ANGELES--(BUSINESS WIRE)---- $AQST #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST)

4 months ago - Business Wire

FRIDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics,...

Los Angeles, California--(Newsfile Corp. - April 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutic...

4 months ago - Newsfile Corp

AQST Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Aquestive Therapeutics, Inc. Investors of Class Ac...

New York, New York--(Newsfile Corp. - April 28, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive"...

4 months ago - Newsfile Corp

FRIDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutic...

Los Angeles, California--(Newsfile Corp. - April 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutic...

4 months ago - Newsfile Corp

Rosen, Top Ranked Global Investor Counsel, Encourages Aquestive Therapeutics, Inc. Investors with Losses Over $100K t...

New York, New York--(Newsfile Corp. - April 25, 2021) - WHY: New York, N.Y., April 25, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeu...

4 months ago - Newsfile Corp

Aquestive Therapeutics to Report First Quarter 2021 Financial Results and Recent Business Highlights on May 4 and Hos...

WARREN, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address pati...

5 months ago - GlobeNewsWire